INZY Stock Forecast & Price Target

Inozyme Pharma Inc. has demonstrated a positive shift in its financial outlook, with the FY25 EPS estimate improved to ($1.40) from ($1.82), reflecting enhanced expectations for the company’s performance. The company's lead product candidate, INZ-701, shows significant promise, evidenced by positive Phase 3 trial results anticipated by 1Q26, which could lead to its first approval in an underserved market, thereby extending the cash runway into Q126. Additionally, the clinical efficacy of INZ-701 is underscored by improved survival rates in treated infants and favorable results in adult trials, positioning Inozyme Pharma for potential long-term growth through continued advancements in both ENPP1 and ABCC6 deficiency programs.

Inozyme Pharma Inc. faces significant financial challenges, with its cash reserves declining from $132 million to $113 million over a single quarter, coupled with an outstanding debt of $45 million from a previous loan agreement. The company's ongoing clinical development is further compromised by delays attributed to COVID-19, negatively impacting projected timelines and potential revenues, particularly for the ABCC6 and Calciphylaxis programs. Additionally, a lowered probability of success for the ABCC6 program, now estimated at 30%, indicates a bleak outlook for profitability, which is not expected for several years.